Last reviewed · How we verify
Placebo of DWJ1464
A placebo formulation containing no active pharmaceutical ingredient, used as a control in clinical trials.
At a glance
| Generic name | Placebo of DWJ1464 |
|---|---|
| Sponsor | Daewoong Pharmaceutical Co. LTD. |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebos are inert substances administered in controlled studies to establish baseline effects and distinguish true drug efficacy from placebo response. They serve as the comparator arm in randomized controlled trials to measure the actual therapeutic benefit of the investigational drug DWJ1464.
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Efficacy and Safety of DWJ1464 in Patients with Chronic Liver Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo of DWJ1464 CI brief — competitive landscape report
- Placebo of DWJ1464 updates RSS · CI watch RSS
- Daewoong Pharmaceutical Co. LTD. portfolio CI